Renal denervation for drug-resistant hypertension: Suffering its original sin, seeking redemption

Canadian Journal of Cardiology

Volumn 30, Issue 5, 2014, Pages 476-478

  Floras, John S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RESISTANT HYPERTENSION; EDITORIAL; EVOLUTION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; PATHOPHYSIOLOGY;

ADULT; BLOOD PRESSURE; DENERVATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899946477     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.02.008     Document Type: Editorial

References (26)

1. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
2. DiBona G.F., Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010, 298:R245-R253.
3. Schlaich M.P., Schmieder R.E., Bakris G., et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol 2013, 62:2031-2045.
4. Froeschl M., Hadziomerovic A., Ruzicka M. Percutaneous renal sympathetic denervation: 2013 and beyond. Can J Cardiol 2014, 30:64-74.
5. Pedrosa R.P., Drager L.F., Gonzaga C.C., et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011, 58:811-817.
6. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 11:e510-e526.
7. Clark D., Ahmed M.I., Calhoun D.A. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012, 28:318-325.
8. Esler M., Jennings G., Korner P., et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988, 11:3-20.
9. Ramchandra R., Hood S.G., Denton D.A., et al. Basis for the preferential activation of cardiac sympathetic nerve activity in heart failure. Proc Natl Acad Sci U S A 2009, 106:924-928.
10. Ng A.V., Callister R., Johnson D.G., Seals D.R. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 1993, 21:498-503.
11. Esler M. Sympathetic nervous activation in essential hypertension: commonly neglected as a therapeutic target, usually ignored as a drug side effect. Hypertension 2010, 55:1090-1091.
12. Grassi G., Seravalle G., Dell'Oro R., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761-1769.
13. Menon D.V., Arbique D., Wang Z., et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab 2009, 94:1361-1366.
14. Grassi G., Seravalle G., Turri C., Bolla G., Mancia G. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003, 41:558-562.
15. Struck J., Muck P., Trubger D., et al. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 2002, 20:1143-1149.
16. Schroeder C., Heusser K., Brinkmann J., et al. Truly refractory hypertension. Hypertension 2013, 62:231-235.
17. Floras J.S., Jones J.V., Johnston J.A., et al. Arousal and the circadian rhythm of blood pressure. Clin Sci Mol Med Suppl 1978, 4:395s-397s.
18. Hering D., Lambert E.A., Marusic P., et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013, 61:457-464.
19. Brinkmann J., Heusser K., Schmidt B.M., et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 2012, 60:1485-1490.
20. Hart E.C., McBryde F.D., Burchell A.E., et al. Translational examination of changes in baroreflex function after renal denervation in hypertensive rats and humans. Hypertension 2013, 62:533-541.
21. McGowan C.L., Murai H., Miller P.J., et al. Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension. Heart 2013, 99:240-246.
22. Carter J.R., Ray C.A., Downs E.M., Cooke W.H. Strength training reduces arterial blood pressure but not sympathetic neural activity in young normotensive subjects. J Appl Physiol 2003, 94:2212-2216.
23. Savard S., Frank M., Bobrie G., et al. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol 2012, 60:2422-2424.
24. Pokushalov E., Romanov A., Corbucci G., et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012, 60:1163-1170.
25. The state of US health 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013, 310:591-608. US Burden of Disease Collaborators.
26. Khan N.A., Herman R.J., Quinn R.R., et al. Renal denervation therapy for the treatment of resistant hypertension: a position statement by the Canadian Hypertension Education Program. Can J Cardiol 2014, 30:16-21.